4

$ABT · Abbott Laboratories

October 2, 2026 · AI-analyzed SEC filing · Verify material figures against the official SEC.gov filing

This is a Form 4 filing disclosing a change in beneficial ownership by Kevin T. Conroy, a director of Abbott Laboratories. The filing reports that on September 30, 2026, Conroy acquired 318 stock equivalent units at a price of $98.83 per unit. These units were credited to a stock equivalent unit account under a grantor trust established by the director.

The stock equivalent units represent director fees and earn the same return as if the fees were invested in Abbott common stock. They are generally paid in cash when the director reaches age 65 or upon retirement from the board. Following the reported transaction, Conroy beneficially owned 551 stock equivalent units directly. The balance also includes units acquired through a dividend reinvestment feature.

The form was filed on October 2, 2026, as required under Section 16(a) of the Securities Exchange Act of 1934, which covers reporting of transactions by company insiders.

Get filings like this before the market reacts.

Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.

Start your free trial →